Helping you excel as an immunizer by delivering up-to-the minute news, tools, and resources.
On September 18, 2014, APhA hosted a webinar update provided by the CDC on the new CDC recommendations concerning pneumococcal vaccination. The new recommendations include adults 65 years and older be vaccinated with 13-valent pneumococcal conjugate vaccine (PCV13, Prevnar-13). The 23-valent polysaccharide vaccine (PPSV23, Pneumovax) continues to be recommended for adults 65 years of age or older with the PPSV23 vaccine ideally given 6-12 months after PCV13 vaccine. This is an informational briefing and does not provide CE credit. Additional information to help you manage the new recommendations can be found at the below sites and will be added to pharmacist.com as they become available.
In a recent MMWR (dated September 19) CDC released new pneumococcal vaccination recommendations. Adults 65 years of age or older are now recommended to get the pneumococcal conjugate vaccine (PCV13, Prevnar-13®), followed by the pneumococcal polysaccharide vaccine (PPSV23, Pneumovax®23) 6-12 months later. As adults start to visit their healthcare professionals for their annual flu shot, it’s also an opportunity to raise awareness for the importance of pneumococcal vaccination and to educate healthcare professionals and the general public on the new recommendation.
Attached are key points regarding pneumococcal vaccination recommendations:
Ask the Experts - Answers to your immunization questions, organized by topic.
CDC Vaccine Resources - schedules, recommendations, Vaccine Information Statements
Immunization Action Coalition - news, patient handouts, clinic management resources
Vaccine Adverse Events Reporting System (VAERS) - national vaccine safety surveillance system
Pharmacist authority to immunize - by type of immunization
Pharmacist authority to administer influenza vaccine - number of states authorizing pharmacist-delivered influenza vaccine vs. number of pharmacists trained to do so
Role of community pharmacies/pharmacists in U.S. vaccine delivery - includes regulatory considerations, best practices, and what's on the horizon
With the Food and Drug Administration’s (FDA) approval of intradermal influenza vaccine, many questions have been asked of the American Pharmacists Association (APhA) about additional training for pharmacists. This is a relatively easy vaccine to administer and we have developed a worksheet from material provided by the manufacturer and other resources, as well as providing a video developed by the manufacturer, to explain this process.
FluMist® is administered intranasally; active inhalation (i.e., sniffing) by the patient is not required. Watch this video to learn how to store FluMist in your office, and how to administer it to your eligible patients 2 years to 49 years old. Download patient information.